Skip to main content

Articles

Page 61 of 66

  1. Searching for novel molecular markers that dependably predict or indicate responses of human cancer cells to epidermal growth factor receptor (EGFR)-targeted therapy is strongly warranted. The purpose of the c...

    Authors: Yang Lu, Ke Liang, Xinqun Li and Zhen Fan
    Citation: Molecular Cancer 2007 6:63
  2. Oral leukoplakia is a precancerous change developed in the oral mucosa, and the mechanism that oral leukoplakia becomes malignant through atypical epithelium is not known. Here we compared the β-catenin expres...

    Authors: Kosei Ishida, Satoshi Ito, Naoyuki Wada, Hiroyo Deguchi, Tsuyoshi Hata, Masaru Hosoda and Tsutomu Nohno
    Citation: Molecular Cancer 2007 6:62
  3. It is more and more recognized that hypoxia plays a role in the resistance of cancer cells to chemotherapy. However, the mechanisms underlying this resistance still need deeper understanding. The aim of this s...

    Authors: Jean-Philippe Cosse, Audrey Sermeus, Kayleen Vannuvel, Noelle Ninane, Martine Raes and Carine Michiels
    Citation: Molecular Cancer 2007 6:61
  4. Multiple myeloma (MM) is a common hematological malignancy which remains incurable due to both intrinsic and acquired resistance to conventional or more novel drugs. Estrogenic and antiestrogenic compounds are...

    Authors: Brigitte Sola and Jack-Michel Renoir
    Citation: Molecular Cancer 2007 6:59
  5. Drug resistance is a major problem in cancer chemotherapy. Acquisition of chemo-resistance not only reduces the effectiveness of drugs, but also promotes side effects and markedly reduces the patient's quality...

    Authors: Jun Hamaguchi, Hiroaki Nakagawa, Masato Takahashi, Takeaki Kudo, Naoya Kamiyama, Bailong Sun, Takahiro Oshima, Yuji Sato, Kisaburo Deguchi, Satoru Todo and Shin-Ichiro Nishimura
    Citation: Molecular Cancer 2007 6:58
  6. The use of retinoids as anti-cancer agents has been limited due to resistance and low efficacy. The dynamics of nuclear receptor coregulation are incompletely understood. Cell-and context-specific activities o...

    Authors: Kelly C Heim, Kristina A White, Dexin Deng, Craig R Tomlinson, Jason H Moore, Sarah J Freemantle and Michael J Spinella
    Citation: Molecular Cancer 2007 6:57
  7. The presence of EGFR kinase domain mutations in a subset of NSCLC patients correlates with the response to treatment with the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Although most EGFR mutatio...

    Authors: Matheus M de Gunst, Marielle I Gallegos-Ruiz, Giuseppe Giaccone and Jose Antonio Rodriguez
    Citation: Molecular Cancer 2007 6:56
  8. Neuroblastoma (NB) is an extra-cranial solid tumour of childhood. In spite of the good clinical response to first-line therapy, complete eradication of NB cells is rarely achieved. Thus, new therapeutic strate...

    Authors: Roberta Carosio, Guendalina Zuccari, Isabella Orienti, Salvatore Mangraviti and Paolo G Montaldo
    Citation: Molecular Cancer 2007 6:55
  9. Colorectal cancer develops through two main genetic instability pathways characterized by distinct pathologic features and clinical outcome.

    Authors: Giovanni Lanza, Manuela Ferracin, Roberta Gafà, Angelo Veronese, Riccardo Spizzo, Flavia Pichiorri, Chang-gong Liu, George A Calin, Carlo M Croce and Massimo Negrini
    Citation: Molecular Cancer 2007 6:54
  10. Testicular germ cell tumors (TGCTs) respond well to cisplatin-based chemotherapy and show a low incidence of acquired resistance compared to most somatic tumors. The reasons for these specific characteristics ...

    Authors: Nur Duale, Birgitte Lindeman, Mitsuko Komada, Ann-Karin Olsen, Ashild Andreassen, Erik J Soderlund and Gunnar Brunborg
    Citation: Molecular Cancer 2007 6:53
  11. Fusion of the MOZ and TIF2 genes by an inv (8) (p11q13) translocation has been identified in patients with acute mixed-lineage leukemia. Characterization of the molecular structure of the MOZ-TIF2 fusion prote...

    Authors: Hong Yin, Jonathan Glass and Kerry L Blanchard
    Citation: Molecular Cancer 2007 6:51
  12. Efforts aimed at deciphering the molecular basis of complex disease are underpinned by the availability of high throughput strategies for the identification of biomolecules that drive the disease process. The ...

    Authors: David Murray, Peter Doran, Padraic MacMathuna and Alan C Moss
    Citation: Molecular Cancer 2007 6:50
  13. Epigenetic silencing of the RAS association domain family 1A (RASSF1A) tumor suppressor gene promoter has been demonstrated in renal cell carcinoma (RCC) as a result of promoter hypermethylation. Contradictory re...

    Authors: Inga Peters, Kristina Rehmet, Nadine Wilke, Markus A Kuczyk, Jörg Hennenlotter, Tyark Eilers, Stefan Machtens, Udo Jonas and Jürgen Serth
    Citation: Molecular Cancer 2007 6:49
  14. Resistance to modern adjuvant treatment is in part due to the failure of programmed cell death. Therefore the molecules that execute the apoptotic program are potential targets for the development of anti-canc...

    Authors: Hiroyuki Kashiwagi, Jonathan E McDunn, Peter O Simon Jr, Peter S Goedegebuure, Jinbin Xu, Lynne Jones, Katherine Chang, Fabian Johnston, Kathryn Trinkaus, Richard S Hotchkiss, Robert H Mach and William G Hawkins
    Citation: Molecular Cancer 2007 6:48
  15. Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors. They vary in regard to their age at first symptom, localization, morphology and prognosis. Genetic data also suggests he...

    Authors: Emmanuel Rousseau, Thomas Palm, Francesco Scaravilli, Marie-Magdeleine Ruchoux, Dominique Figarella-Branger, Isabelle Salmon, David Ellison, Catherine Lacroix, Françoise Chapon, Jacqueline Mikol, Miikka Vikkula and Catherine Godfraind
    Citation: Molecular Cancer 2007 6:47
  16. Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy affecting children. Despite significant progress and success in the treatment of ALL, a significant number of children continue to...

    Authors: Tapas K Sengupta, Gilles M Leclerc, Ting Ting Hsieh-Kinser, Guy J Leclerc, Inderjit Singh and Julio C Barredo
    Citation: Molecular Cancer 2007 6:46
  17. The epigenetics of ovarian carcinogenesis remains poorly described. We have in the present study investigated the promoter methylation status of 13 genes in primary ovarian carcinomas (n = 52) and their in vitro ...

    Authors: Qinghua Wu, Ragnhild A Lothe, Terje Ahlquist, Ilvars Silins, Claes G Tropé, Francesca Micci, Jahn M Nesland, Zhenhe Suo and Guro E Lind
    Citation: Molecular Cancer 2007 6:45
  18. Angiogenesis is a fundamental process that allows tumor growth by providing nutrients and oxygen to the tumor cells. Beyond the oxygen diffusion limit from a capillary blood vessel, tumor cells become apoptoti...

    Authors: Thaysa Paschoalin, Adriana K Carmona, Elaine G Rodrigues, Vitor Oliveira, Hugo P Monteiro, Maria A Juliano, Luiz Juliano and Luiz R Travassos
    Citation: Molecular Cancer 2007 6:44
  19. Sovereign power is retained and shared by the citizens of a country. Using electoral tools, governing structures are formed to ensure protection of national interests. As with any institution, proper control o...

    Authors: Shawn Mathur and Christian Schmidt
    Citation: Molecular Cancer 2007 6:43
  20. The role of TNF-α in affecting the fate of tumors is controversial, while some studies have reported apoptotic or necrotic effects of TNF-α, others provide evidence that endogenous TNF-α promotes growth and de...

    Authors: Pabbisetty Sudheer Kumar, Anjali Shiras, Gowry Das, Jayashree C Jagtap, Vandna Prasad and Padma Shastry
    Citation: Molecular Cancer 2007 6:42
  21. The cRGD peptide is a promising probe for early non-invasive detection of tumors. This study aimed to demonstrate how RAFT-c(-RGDfK-)4, a molecule allowing a tetrameric presentation of cRGD, improved cRGD-targeti...

    Authors: Zhao-Hui Jin, Véronique Josserand, Stéphanie Foillard, Didier Boturyn, Pascal Dumy, Marie-Christine Favrot and Jean-Luc Coll
    Citation: Molecular Cancer 2007 6:41
  22. LIM kinase 1 (LIMK1), a LIM domain containing serine/threonine kinase, modulates actin dynamics through inactivation of the actin depolymerizing protein cofilin. Recent studies have indicated an important role...

    Authors: Monica Davila, Darshana Jhala, Debashis Ghosh, William E Grizzle and Ratna Chakrabarti
    Citation: Molecular Cancer 2007 6:40
  23. The androgen receptor (AR) plays critical roles in both androgen-dependent and castrate-resistant prostate cancer (PCa). However, little is known about AR target genes that mediate the receptor's roles in dise...

    Authors: Unnati Jariwala, Jennifer Prescott, Li Jia, Artem Barski, Steve Pregizer, Jon P Cogan, Armin Arasheben, Wayne D Tilley, Howard I Scher, William L Gerald, Grant Buchanan, Gerhard A Coetzee and Baruch Frenkel
    Citation: Molecular Cancer 2007 6:39
  24. The androgen receptor is a ligand-induced transcriptional factor, which plays an important role in normal development of the prostate as well as in the progression of prostate cancer to a hormone refractory st...

    Authors: Katia Margiotti, Latif A Wafa, Helen Cheng, Giuseppe Novelli, Colleen C Nelson and Paul S Rennie
    Citation: Molecular Cancer 2007 6:38
  25. The normal human prostate glandular epithelium has the unique function of accumulating high levels of zinc. In prostate cancer this capability is lost as an early event in the development of the malignant cell...

    Authors: Mohamed M Desouki, Joseph Geradts, Beatrice Milon, Renty B Franklin and Leslie C Costello
    Citation: Molecular Cancer 2007 6:37
  26. A novel alkylating agent, temozolomide, has proven efficacious in the treatment of malignant gliomas. However, expression of O 6 -methylguanine-DNA methyltransferase (MGMT) r...

    Authors: Ken Sasai, Tsuyoshi Akagi, Eiko Aoyanagi, Kouichi Tabu, Sadao Kaneko and Shinya Tanaka
    Citation: Molecular Cancer 2007 6:36
  27. Burkitt's lymphoma (BL) is a heterogeneous group of highly aggressive mature B-cell malignancies. It is characterized by a high rate of turnover of malignant cells and deregulation of the c-myc gene. It is typ...

    Authors: Delong Liu, Josif Shimonov, Suneeta Primanneni, Yongrong Lai, Tauseef Ahmed and Karen Seiter
    Citation: Molecular Cancer 2007 6:35
  28. The urokinase receptor (uPAR) mediates a diverse array of cellular processes including several events involved in prostate cancer metastasis. Many of these activities are initiated or enhanced by uPAR binding ...

    Authors: Mohammad Hasanuzzaman, Robert Kutner, Siamak Agha-Mohammadi, Jakob Reiser and Inder Sehgal
    Citation: Molecular Cancer 2007 6:34
  29. Acute myeloid leukemia (AML) cells are characterized by non-mutated TP53, high levels of Hdm2, and frequent mutation of the Flt3 receptor tyrosine kinase. The juxtamembrane mutation of FLT3 is the strongest indep...

    Authors: Line Wergeland, Gry Sjøholt, Ingvild Haaland, Randi Hovland, Øystein Bruserud and Bjørn Tore Gjertsen
    Citation: Molecular Cancer 2007 6:33
  30. Correlations of disease phenotypes with glycosylation changes have been analysed intensively in the tumor biology field. Glycoforms potentially associated with carcinogenesis, tumor progression and cancer meta...

    Authors: Takeaki Kudo, Hiroaki Nakagawa, Masato Takahashi, Jun Hamaguchi, Naoya Kamiyama, Hideki Yokoo, Kazuaki Nakanishi, Takahito Nakagawa, Toshiya Kamiyama, Kisaburo Deguchi, Shin-Ichiro Nishimura and Satoru Todo
    Citation: Molecular Cancer 2007 6:32
  31. Relapse due to chemoresistant residual disease is a major cause of death in acute myelogenous leukemia (AML). The present study was undertaken to elucidate the molecular mechanisms of chemoresistance by compar...

    Authors: Tien-sheng Huang, Line M Myklebust, Endre Kjarland, Bjørn Tore Gjertsen, Frederic Pendino, Øystein Bruserud, Stein Ove Døskeland and Johan R Lillehaug
    Citation: Molecular Cancer 2007 6:31
  32. Mutations of the epidermal growth factor receptor (EGFR) are a possible molecular target for cancer therapy. EGFR is frequently amplified in glioblastomas and 30 to 40% of glioblastomas also express the deleti...

    Authors: Dimitri G Trembath, Anita Lal, David J Kroll, Nicholas H Oberlies and Gregory J Riggins
    Citation: Molecular Cancer 2007 6:30
  33. Inflammation is increasingly recognized as an important component of tumorigenesis, although the mechanisms involved are not fully characterized. The invasive capacity of cancers is reflected in the classic me...

    Authors: José-Ignacio Arias, María-Angeles Aller and Jaime Arias
    Citation: Molecular Cancer 2007 6:29
  34. The latency-associated nuclear antigen (LANA-1) of Human Herpes Virus 8 (HHV-8), alternatively called Kaposi Sarcoma Herpes Virus (KSHV) is constitutively expressed in all HHV-8 infected cells. LANA-1 accumula...

    Authors: György Stuber, Karin Mattsson, Emilie Flaberg, Emrah Kati, Laszlo Markasz, Julie A Sheldon, George Klein, Thomas F Schulz and Laszlo Szekely
    Citation: Molecular Cancer 2007 6:28
  35. Bright/ARID3A is a nuclear matrix-associated transcription factor that stimulates immunoglobulin heavy chain (IgH) expression and Cyclin E1/E2F-dependent cell cycle progression. Bright positively activates IgH...

    Authors: Danjuan Lin, Gregory C Ippolito, Rui-Ting Zong, James Bryant, Janet Koslovsky and Philip Tucker
    Citation: Molecular Cancer 2007 6:23
  36. The blood-brain tumor barrier (BTB) impedes the delivery of therapeutic agents to brain tumors. While adequate delivery of drugs occurs in systemic tumors, the BTB limits delivery of anti-tumor agents into bra...

    Authors: Jinwei Hu, Xiangpeng Yuan, MinHee K Ko, Dali Yin, Manuel R Sacapano, Xiao Wang, Bindu M Konda, Andres Espinoza, Ksenia Prosolovich, John M Ong, Dwain Irvin and Keith L Black
    Citation: Molecular Cancer 2007 6:22
  37. microRNAs (miRNAs) are a group of non-coding single stranded RNAs measuring approximately 22 nucleotides in length that have been found to control cell growth, differentiation and apoptosis. They negatively re...

    Authors: Susanne Cahill, Paul Smyth, Karen Denning, Richard Flavin, Jinghuan Li, Astrid Potratz, Simone M Guenther, Richard Henfrey, John J O'Leary and Orla Sheils
    Citation: Molecular Cancer 2007 6:21
  38. Robust Hedgehog (Hh) signaling has been implicated as a common feature of human prostate cancer and an important stimulus of tumor growth. The role of Hh signaling has been studied in several xenograft tumor m...

    Authors: Jerry Gipp, Guangyu Gu, Curtis Crylen, Susan Kasper and Wade Bushman
    Citation: Molecular Cancer 2007 6:19
  39. Nidogens are highly conserved proteins of basement membranes. Two nidogen proteins, nidogen 1 and nidogen 2, are known in mammals.

    Authors: Linda Ulazzi, Silvia Sabbioni, Elena Miotto, Angelo Veronese, Angela Angusti, Roberta Gafà, Stefano Manfredini, Fabio Farinati, Takako Sasaki, Giovanni Lanza and Massimo Negrini
    Citation: Molecular Cancer 2007 6:17
  40. The PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) tumor suppressor gene is frequently mutated or deleted in a wide variety of solid tumors, and these cancers are generally more aggressive and di...

    Authors: Pei-Yin Lin, Susan P Fosmire, See-Hyoung Park, Jin-Young Park, Shairaz Baksh, Jaime F Modiano and Robert H Weiss
    Citation: Molecular Cancer 2007 6:16
  41. The Cox proportional hazards model is the most widely used model for survival analysis because of its simplicity. The fundamental assumption in this model is the proportionality of the hazard function. When th...

    Authors: Farid E Ahmed, Paul W Vos and Don Holbert
    Citation: Molecular Cancer 2007 6:15
  42. The consecutive acquisition of genetic alterations characterizes neoplastic processes. As a consequence of these alterations, molecular interactions are reprogrammed in the context of highly connected and regu...

    Authors: Pilar Hernández, Xavier Solé, Joan Valls, Víctor Moreno, Gabriel Capellá, Ander Urruticoechea and Miguel Angel Pujana
    Citation: Molecular Cancer 2007 6:13

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions